NCT05450601View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 11, 2023

Study Completion Date

December 11, 2023

Conditions
Hypertension
Interventions
DRUG

HCP2102-1

Take once daily for 2 weeks orally

DRUG

HPP2104-1

Placebo drug. Take once daily for 2 weeks orally

DRUG

HCP2102-2

Take once daily for 6 weeks orally

DRUG

HPP2104-2

Placebo drug. Take once daily for 6 weeks orally

DRUG

RLD2106-1

Take once daily for 2 weeks orally

DRUG

HPP2103-1

Placebo drug. Take once daily for 2 weeks orally

DRUG

RLD2106-2

Take once daily for 6 weeks orally

DRUG

HPP2103-2

Placebo drug. Take once daily for 6 weeks orally

Trial Locations (1)

02447

Kyung Hee University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY